Core Viewpoint - Xizang Pharmaceutical Co., Ltd. has seen a stock price increase of 5.02%, reaching 57.50 CNY per share, with a trading volume of 633 million CNY and a turnover rate of 3.56%, resulting in a total market capitalization of 18.533 billion CNY [1] Company Overview - Xizang Pharmaceutical Co., Ltd. is located in Lhasa Economic and Technological Development Zone, Tibet, and was established on July 14, 1999, with its listing date on July 21, 1999. The company primarily engages in pharmaceutical manufacturing [1] - The main revenue composition of the company is 99.80% from drug sales and 0.20% from other supplementary sources [1] Shareholder Information - Among the top ten circulating shareholders of Xizang Pharmaceutical, Huaxia Fund's Huaxia Industry Prosperity Mixed Fund (003567) holds 1.9036 million shares, unchanged from the previous period, accounting for 0.59% of circulating shares. The estimated floating profit today is approximately 5.235 million CNY [2] - The Huaxia Industry Prosperity Mixed Fund was established on February 4, 2017, with a latest scale of 7.261 billion CNY. Year-to-date returns are 49.16%, ranking 881 out of 8174 in its category; the one-year return is 99.56%, ranking 463 out of 7981; and since inception, the return is 357.78% [2] Fund Management - The fund manager of Huaxia Industry Prosperity Mixed Fund is Zhong Shuai, who has been in the position for 5 years and 48 days. The total asset scale of the fund is 8.253 billion CNY, with the best fund return during his tenure being 167.61% and the worst being 8.67% [3]
西藏药业股价涨5.02%,华夏基金旗下1只基金位居十大流通股东,持有190.36万股浮盈赚取523.5万元